The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity

Molecular Cancer Research

Volumn 6, Issue 5, 2008, Pages 725-734

  Willis, Amanda L ^a   Tran, Nhan L ^a   Chatigny, Julie M ^a   Charlton, Nichole ^b,d   Vu, Hong ^b,e   Brown, Sharron A N ^b   Black, Michael A ^c   McDonough, Wendy S ^a   Fortin, Shannon P ^a   Niska, Joshua R ^a   Winkles, Jeffrey A ^b   Cunliffe, Heather E ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d WASHINGTON UNIVERSITY   (United States)

^e IOMAI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14 RECEPTOR; LIGAND; MUTANT PROTEIN; PROTEIN FN14TCT; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; TWEAK PROTEIN; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER INVASION; CONTROLLED STUDY; DELETION MUTANT; DNA FINGERPRINTING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR GENETICS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TAXONOMY; ADENOVIRUS; BREAST TUMOR; CHEMISTRY; DNA MICROARRAY; DOSE RESPONSE; IMMUNOHISTOCHEMISTRY; METABOLISM; TUMOR CELL LINE;

ADENOVIRIDAE; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS;

EID: 51049115805     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0005     Document Type: Article

References (50)

1. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
2. Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37:899-905.
3. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
4. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
5. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
6. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
7. Winkles JA, Tran NL, Brown SA, Stains N, Cunliffe HE, Berens ME. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007;12:2761-71.
8. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40:1-16.
9. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001;15:837-46.
10. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004;64:8968-72.
11. Tran NL, McDonough WS, Donohue PJ, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003;162:1313-21.
12. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;280:3483-92.
13. Wang S, Zhan M, Yin J, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006;25:3346-56.
14. Watts GS, Tran NL, Berens ME, et al. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 2007;121:2132-9.
15. Tran NL, McDonough WS, Savitch BA, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Res 2006;66:9535-42.
16. Michaelson JS, Cho S, Browning B, et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005;24:2613-24.
17. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
18. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
19. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
20. Allred DC, Brown P, Medina D. The origins of estrogen receptor α-positive and estrogen receptor α-negative human breast cancer. Breast Cancer Res 2004;6:240-5.
21. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005;123:16-20.
22. McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002;117:935-43.
23. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 2003;106:8-16.
24. Thompson EW, Paik S, Brunner N, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992;150:534-44.
25. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
26. Platet N, Prevostel C, Derocq D, Joubert D, Rochefort H, Garcia M. Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer 1998;75:750-6.
27. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
28. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-κB activation. Biochem J 2003;371:395-403.
29. Han S, Yoon K, Lee K, et al. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-κB through TNF receptor-associated factors. Biochem Biophys Res Commun 2003;305:789-96.
30. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-κB2 p100 processing and long lasting NF-κB activation. J Biol Chem 2003;278:36005-12.
31. Mehl AM, Jones M, Rowe M, Brennan P. Characterization of a CD40-dominant inhibitory receptor mutant. J Immunol 2001;167:6388-93.
32. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-κB signaling module. Oncogene 2006;25:6706-16.
33. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995;270:14255-8.
34. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598-607.
35. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
36. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
37. Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 2002;62:652-5.
38. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor κB (NF-κB) signaling in breast cancer. J Cell Physiol 2006;209:645-52.
39. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000;19:4159-69.
40. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
41. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
42. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
43. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997;17:1535-42.
44. Leo E, Welsh K, Matsuzawa S, et al. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-κB and Jun N-terminal kinase activation. J Biol Chem 1999;274:22414-22.
45. Wietek C, O'Neill LA. Diversity and regulation in the NF-κB system. Trends Biochem Sci 2007;32:301-9.
46. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
47. Cunliffe HE, Ringner M, Bilke S, et al. The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res 2003;63:7158-66.
48. Meighan-Mantha RL, Hsu DK, Guo Y, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999;274:33166-76.
49. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
50. Hastie T, Tibshirani R, Friedman J. Note on "Comparison of model selection for regression" by Vladimir Cherkassky and Yunqian Ma. Neural Comput 2003;15:1477-80.